Research programme: acne therapies - Corixa
Latest Information Update: 15 Aug 2007
At a glance
- Originator Corixa Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Acne
Most Recent Events
- 18 Apr 2001 New profile
- 18 Apr 2001 Preclinical development for Acne in USA (unspecified route)